Filing Flows › Comparisons › RGNX vs BSEM
Regenxbio vs BioStem Technologies: RGNX and BSEM compared
Regenxbio is the larger company: $9.2M of revenue in its latest quarter (Q3 2026) against $7.9M for BioStem Technologies (Q2 2026). BioStem Technologies is growing faster (-28% against -69% a year earlier). BioStem Technologies is more profitable, with an operating margin of -106.3% against -387.8%.
Where the money goes: RGNX and BSEM
Regenxbio (RGNX) · Q3 2026
Regenxbio, Q3 2026: revenue $9.2M (-69% year over year), operating margin -387.8%, net loss $40.7M, operating cash flow $38.6M. The chart follows the revenue to costs, profit and cash.
BioStem Technologies (BSEM) · Q2 2026
BioStem Technologies, Q2 2026: revenue $7.9M (-28% year over year), operating margin -106.3%, net loss $9.0M. The chart follows the revenue to costs, profit and cash.
| Regenxbio (RGNX) | BioStem Technologies (BSEM) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $9.2M | $7.9M |
| Revenue growth, Y/Y | -69% | -28% |
| Operating margin | -387.8% | -106.3% |
| Net earnings | −$40.7M | −$9.0M |
| Net margin | -444.6% | -113.6% |
| Operating cash flow | $38.6M | — |
| Free cash flow | $38.4M | — |
Where the revenue comes from
Regenxbio
- License and Service: $5.2M (57%)
- Service: $3.9M (43%)
BioStem Technologies
- Hospital: $6.7M (85%)
- Physician Office: $1.1M (14%)
- Other: $89K (1%)
Questions
Which is bigger, Regenxbio or BioStem Technologies?
Regenxbio is the larger company: $9.2M of revenue in its latest quarter (Q3 2026) against $7.9M for BioStem Technologies (Q2 2026).
Is Regenxbio or BioStem Technologies growing faster?
BioStem Technologies is growing faster (-28% against -69% a year earlier).
Which is more profitable, Regenxbio or BioStem Technologies?
BioStem Technologies is more profitable, with an operating margin of -106.3% against -387.8%.
More: Regenxbio earnings · how Regenxbio makes money · BioStem Technologies earnings · how BioStem Technologies makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.